RecruitingPhase 2Phase 3NCT06798363
Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma
Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma： a Prospective Study
Sponsor
West China Hospital
Enrollment
40 participants
Start Date
May 2, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The main objective of this study was to determine the efficacy of different doses of propranolol in the treatment of ulcerattion infantile hemangioma (IH).
Eligibility
Min Age: 1 MonthMax Age: 4 Years
Inclusion Criteria2
- all patients with ulcer IH;
- children with ulcer IH treated with propranolol.
Exclusion Criteria2
- \) children with ulcer IH who received other therapeutic interventions were excluded; 2) Children whose families refused to participate in the study; 3) patients with contraindications to oral propranolol, such as allergy to propranolol, severe bradycardia and bronchial asthma; 4) children lost to follow-up during oral propranolol treatment; 5) children unable to oral propranolol or continue to oral propranolol due to other reasons.
- \-
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGpropranolol
different dose
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06798363